Mission:The mission of The Fogarty Institute for Innovation (FII) is to mentor, train and inspire the next generation of medical innovators.
For decades, the U.S. has benefited from being home to the preeminent medical innovation ecosystem in the world. This has ensured access to cutting-edge treatment options for the nation’s citizens, fueled economic growth and job creation and been a critical component of U.S. global technological leadership. Now, that leadership position is at risk. The reasons range from reduced government research funding for medical innovations to increased offshore investments by venture capital firms fed up with an overly burdensome regulatory environment, as well as an entrenched healthcare sector that defends existing, high revenue-generating technologies against competition by new, less-costly alternatives.
In late 2006, Dr. Fogarty founded the Fogarty Institute for Innovation to reverse this trend by energizing the process of medical innovation—with the focus on improving patient care. The Fogarty Institute opened on the El Camino Hospital campus on September 25, 2007. This relationship with the hospital allows innovators access to physicians, surgeons, facilities and patients from all fields of medicine.
Since beginning operations, the Institute has screened over 70 proposals for novel medical technologies, and has selected four especially promising candidates for support by providing access to the Institute’s facilities, and direct mentoring by Dr. Fogarty and other Institute staff members. In these ways, the rate of medical innovation is accelerated, the chances for success are increased, and the time required to deploy revolutionary new treatment options to patients is reduced.
How FII Works:
The Fogarty Institute is a 501(c)(3) educational non-profit dedicated to benefiting patients. Led by a multi-disciplinary team of experts the Institute provides assistance to emerging medical innovators to help translate their ideas into new patient therapies. The Institute offers the following programs:
- INNOVATION CULTIVATION - Handpicked applicants are provided with the environment and resources to develop promising innovations into products that benefit patients. The Institute provides innovators with access to its facility that includes office, lab, and engineering space, and multiple conference rooms. The program’s partnership with El Camino Hospital provides innovators with the unique surgical and clinical exposure needed to make critical, clinically-informed, design modifications. Further, the Institute provides each innovator with both technical and business mentoring from members of its experienced staff, and also assistance in identifying financing through its extensive Silicon Valley network.
- CLINICAL RESEARCH – In 2011, Pamela and Edward Taft made a generous $4 million donation to El Camino Hospital to establish a clinical research capability within the Fogarty Institute. The Taft Center for Clinical Research supports clinical trials by providing efficient, high quality management services and provides members of the community the opportunity to participate in trials for revolutionary, cutting-edge treatment options. The Clinical Research program provides an alternative to the typically slow moving pace of research in an academic setting. The Taft Research Center currently runs clinical trials for El Camino Hospital and outside sponsors in cardiovascular disease and oncology.
- EDUCATION - The Institute shares its successful experience with the broader community through various educational offerings (e.g. workshops, seminars, etc.) and with the medical community through sponsored post-graduate fellowships and an internship program
Companies supported by FII:
BioParadox: Point-of-care biologic treatments for cardiovascular disease.
Clear Ear: Cost-effective total ear care system.
First Pulse Medical: Developing a novel technology platform to improve fetal monitoring during labor and delivery. The intrauterine technology utilizes a non-fetally invasive sensor to capture valuable fetal vital signs that will give obstetricians critical information related to fetal well-being.
HeartFlow: Developer of patient-specific modeling technology that non-invasively assesses coronary blood flow in patients to determine if surgical repair is necessary. HeartFlow technology has the potential to eliminate almost a million unnecessary cardiac surgeries annually.
InPress Technologies: Developing a single-use medical device to treat postpartum hemorrhage (PPH) by specifically addressing uterine atony. By avoiding the use of pharmaceuticals, hysterectomy, or other invasive surgical procedures, the InPress can dramatically reduce the cost of healthcare during childbirth and save women's lives.
InterVene: Percutaneous approach to restoring valve competency in the deep leg veins.
Materna Medical: Working to reduce the incidence of childbirth-related injuries to women during vaginal delivery with a device designed to prevent vaginal tearing and pelvic floor damage during childbirth.
Medical Cue: The NeoCue System solves a major need in newborn monitoring and resuscitation by automatically sensing key physiologic data and offering decision guidance through neonatal resuscitation and rapid venous access.
Mitre Medical: Focused on developing innovative solutions to treat structural heart disease in humans and companion animals, Mitre's lead program The Mitral Touch(R) is an elegant, less-invasive surgical solution to treat functional mitral regurgitation and potentially prevent the onset of congestive heart failure.
Niveus Medical: This company is developing novel devices for preventing muscle deterioration in patients requiring extended periods of critical care. The technology will shorten hospital stays, and save costs by reducing in-hospital patient morbidity.
Medical Sewing Solutions, LLC: This company is developing a miniaturized sewing machine for use in latharoscopic surgery. This technology will offer surgeons the ability to place a continuous chain of stitches with one pull of a trigger to produce one stitch.
PQ Bypass: This company has developed catheters and stent grafts to perform a fully percutaneous femoral artery bypass. The PQ Bypass treatment method will be associated with greatly reduced morbidity and recovery relative to currently available techniques, and will be applicable to approximately 200,000 patients in the US who suffer from peripheral arterial disease.
Prescient Surgical: Working on CleanCision™, a platform that prevents surgical wound infections. The technology targets a patient segment that has the highest risk of infection: obese patients undergoing colorectal surgery.
Vida: This company is harnessing play through technology to advance health care education. They are focused on the digital transformation of science education. Their first product is a fully integrated anatomy and physiology engine.
Board of Directors
Chairman, Director, Founder: Thomas J. Fogarty, M.D
Director: Frederick St. Goar, M.D., F.A.C.C\
Director, Vice Chairman: Lewis Wexler, M.D.
Director, Secretary: John B. Goodrich, J.D., L.L.M.
President and CEO: Ann Fyfe
Chief Operating Officer: Michael Needels
Chief Medical Officer: James Joye, D.O., F.A.C.C.
Clinical Advisor: Christopher K. Zarins, M.D.
Executive Director, Clinical Research: Betty deBettencourt, R.N., M.S
The Fogarty Institute for Innovation is located on the El Camino Hospital Campus in Mountain View California:
2490 Hospital Drive, Suite 310
Mountain View, CA 94040